Invesco’s Immuneering IMRX Stock Holding History

Invesco’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,249	Closed	-$78.7K	–	3861
2023 Q3	$78.7K	Buy	10,249 +24	+0.2%	+$221	﹤0.01%	3753
2023 Q2	$104K	Buy	+10,225	New	+$98.3K	﹤0.01%	3719

Other funds holding IMRX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return

Invesco's IMRX Position: Q4 2023 in Review

Invesco sold out of Immuneering (IMRX) in Q4 2023, closing a stake of 10,249 shares — an estimated $78.7K sold.

Invesco first reported a position in IMRX in Q2 2023 and held it in 2 quarters. The position peaked at $104K in Q2 2023. 52 funds tracked by Wall St. Rank hold IMRX as of Q4 2023.

Invesco reported no remaining Immuneering position as of Q4 2023 after selling out during the quarter.
Invesco sold 10,249 Immuneering shares in Q4 2023, an estimated $78.7K.
Invesco first reported a position in Immuneering in Q2 2023 and held it in 2 quarters.
Invesco's Immuneering position peaked at $104K in Q2 2023.
52 funds tracked by Wall St. Rank held Immuneering as of Q4 2023.

Based on Invesco's 13F filing for Q4 2023, filed 13 Feb 2024.